CHOP researchers have found that multidrug resistant tumors have reduced connections between mitochondria and endoplasmic reticulum, causing signaling dysfunction.

A transformative gift from local philanthropists Steve and Susan Kelly launches first-of-its-kind hub for pediatric cancer immunotherapy.

More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.

CHOP researchers have shown that linking a tumor-killing prodrug to a macromolecular carrier of the Poloxamer family improves retention of the drug in treatment-resistant neuroblastoma tumors.

In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).

The Lilabean Foundation’s support will accelerate pace of translational research, discovery of new treatments for children and young adults with brain tumors.

As we recognize women’s contributions to history during March, meet a few of the inspiring women on the Cancer Center’s team.

CHOP researchers have found that chemo-resistant mesenchymal cells in neuroblastoma might be vulnerable to immunotherapy.

A new study in Nature has documented the longest persistence of CAR T cell therapy to date.

Tracey Jubelirer, MD, is the Medical Director of the inpatient oncology unit at the Middleman Family Pavilion at Children’s Hospital of Philadelphia, King of Prussia.